Announcements Trials
Browse Landscape

Phase

Phase 2 44Phase 3 40Phase 1 39Phase 1/2 36Phase 2/3 4Phase NA 1Phase 4 1

Status

Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Breast Neoplasms 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Albumin-Bound Paclitaxel × Clear all
NCT07076121 2026-04-30

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05254171 2024-11-06

ASPIRE

Panbela Therapeutics, Inc.

Phase 2/3 Recruiting
600 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04037241 2022-04-01

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Sorrento Therapeutics, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Malignant Tumor of Pancreas Metastatic to Liver

NCT01881230 2019-02-21

tnAcity

Celgene

Phase 2/3 Completed
191 enrolled 22 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡